menu
    • menu
    [{"orgOrder":0,"company":"Lava Therapeutics","sponsor":"ProBioGen","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Large molecule","year":"2020","type":"Agreement","leadProduct":"V\u03b39V\u03b42 T cells based antibodies","moa":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Lava Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Lava Therapeutics \/ ProBioGen AG","highestDevelopmentStatusID":"1","companyTruncated":"Lava Therapeutics \/ ProBioGen AG"},{"orgOrder":0,"company":"Lava Therapeutics","sponsor":"Johnson & Johnson","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Large molecule","year":"2020","type":"Collaboration","leadProduct":"V\u03b39V\u03b42 T cells based antibodies","moa":"5 Gamma 9V Delta 2 T Cell","graph1":"Oncology","graph2":"Preclinical","graph3":"Lava Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Lava Therapeutics \/ Johnson & Johnson","highestDevelopmentStatusID":"4","companyTruncated":"Lava Therapeutics \/ Johnson & Johnson"},{"orgOrder":0,"company":"Lava Therapeutics","sponsor":"Novo Ventures","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Large molecule","year":"2020","type":"Series C Financing","leadProduct":"V\u03b39V\u03b42 T cells based antibodies","moa":"5 Gamma 9V Delta 2 T Cell","graph1":"Oncology","graph2":"Preclinical","graph3":"Lava Therapeutics","amount2":0.080000000000000002,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0.080000000000000002,"dosageForm":"","sponsorNew":"Lava Therapeutics \/ Novo Ventures","highestDevelopmentStatusID":"4","companyTruncated":"Lava Therapeutics \/ Novo Ventures"},{"orgOrder":0,"company":"Lava Therapeutics","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Undisclosed","year":"2021","type":"Public Offering","leadProduct":"Gamma-delta bsTCE","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Lava Therapeutics","amount2":0.10000000000000001,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Lava Therapeutics \/ J.P. Morgan","highestDevelopmentStatusID":"6","companyTruncated":"Lava Therapeutics \/ J.P. Morgan"},{"orgOrder":0,"company":"Lava Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"LAVA-051","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Lava Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Lava Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Lava Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Lava Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"LAVA-051","moa":"5 Gamma 9V Delta 2 T Cell","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Lava Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Lava Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Lava Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Lava Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"LAVA-051","moa":"5 Gamma 9V Delta 2 T Cell","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Lava Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Lava Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Lava Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Lava Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"LAVA-051","moa":"5 Gamma 9V Delta 2 T Cell","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Lava Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Lava Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Lava Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Lava Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"LAVA-051","moa":"5 Gamma 9V Delta 2 T Cell","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Lava Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Lava Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Lava Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Lava Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"LAVA-051","moa":"5 Gamma 9V Delta 2 T Cell","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Lava Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Lava Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Lava Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Lava Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"LAVA-051","moa":"CD1d","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Lava Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Lava Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Lava Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Lava Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"LAVA-1207","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Lava Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Lava Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Lava Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Lava Therapeutics","sponsor":"Seagen","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Licensing Agreement","leadProduct":"LAVA-1223","moa":"EGFR","graph1":"Oncology","graph2":"Preclinical","graph3":"Lava Therapeutics","amount2":0.69999999999999996,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0.69999999999999996,"dosageForm":"","sponsorNew":"Lava Therapeutics \/ LAVA Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Lava Therapeutics \/ LAVA Therapeutics"},{"orgOrder":0,"company":"Lava Therapeutics","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Large molecule","year":"2023","type":"Collaboration","leadProduct":"Bispecific Antibody","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Lava Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Lava Therapeutics \/ Janssen Biotech","highestDevelopmentStatusID":"4","companyTruncated":"Lava Therapeutics \/ Janssen Biotech"},{"orgOrder":0,"company":"Lava Therapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Large molecule","year":"2024","type":"Collaboration","leadProduct":"LAVA-1207","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Lava Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Lava Therapeutics \/ Merck & Co","highestDevelopmentStatusID":"5","companyTruncated":"Lava Therapeutics \/ Merck & Co"},{"orgOrder":0,"company":"Lava Therapeutics","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Large molecule","year":"2024","type":"Agreement","leadProduct":"PF-08046052","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Lava Therapeutics","amount2":0.69999999999999996,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.69999999999999996,"dosageForm":"","sponsorNew":"Lava Therapeutics \/ Pfizer Inc","highestDevelopmentStatusID":"6","companyTruncated":"Lava Therapeutics \/ Pfizer Inc"}]

    Find Clinical Drug Pipeline Developments & Deals by Lava Therapeutics

    Menu

    Lava Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Lava Therapeutics

                            Netherlands arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Lava Therapeutics

                            Netherlands arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : PF-08046052

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Pfizer Inc

                            Deal Size : $700.0 million

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            LAVA Announces Pfizer Milestone for PF-08046052 in Clinical Development

                            Details : Lava will receive milestone payments for SGN-EGFRd2 (PF-08046052), evaluated for colorectal neoplasms and non-small-cell lung carcinoma treatment.

                            Brand Name : SGN-EGFRd2

                            Molecule Type : Large molecule

                            Upfront Cash : $50.0 million

                            March 05, 2024

                            Lead Product(s) : PF-08046052

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Pfizer Inc

                            Deal Size : $700.0 million

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Lava Therapeutics

                            Netherlands arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Lava Therapeutics

                            Netherlands arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : LAVA-1207,Pembrolizumab

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : Merck & Co

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            LAVA Announces Collaboration with Merck To Evaluate LAVA-1207 and KEYTRUDA®

                            Details : The collaboration evaluates Merck's KEYTRUDA® (pembrolizumab) with LAVA-1207, targeting PSMA to kill PSMA-positive tumor cells in patients with mCRPC.

                            Brand Name : LAVA-1207

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            January 25, 2024

                            Lead Product(s) : LAVA-1207,Pembrolizumab

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : Merck & Co

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Lava Therapeutics

                            Netherlands arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Lava Therapeutics

                            Netherlands arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Bispecific Antibody

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Johnson & Johnson Innovative Medicine

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            LAVA Therapeutics Announces Selection by Janssen of Lead Gamma-Delta T-Cell Engager Bispecific Antibody to Mov...

                            Details : Under the collaboration, Janssen has chosen a lead gamma-delta T-cell engager bispecific antibody candidate aimed at an undisclosed tumor-associated antigen for further development towards clinical settings for the treatment of cancer.

                            Brand Name : Undisclosed

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            June 01, 2023

                            Lead Product(s) : Bispecific Antibody

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Johnson & Johnson Innovative Medicine

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Lava Therapeutics

                            Netherlands arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Lava Therapeutics

                            Netherlands arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : LAVA-1207

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            LAVA Therapeutics to Present LAVA-1207 Clinical Data at the 2023 ASCO GU Symposium

                            Details : LAVA-1207 is a Gammabody™ that conditionally activates Vgamma9 Vdelta2 T cells upon crosslinking to PSMA to trigger the potent and preferential killing of PSMA-positive tumor cells, including metastatic castration-resistant prostate cancer.

                            Brand Name : LAVA-1207

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            January 23, 2023

                            Lead Product(s) : LAVA-1207

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Lava Therapeutics

                            Netherlands arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Lava Therapeutics

                            Netherlands arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : LAVA-051

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            LAVA Therapeutics to Present On-Mechanism Pharmacodynamics Data from the Phase 1/2a Clinical Trial of LAVA-051...

                            Details : LAVA-051, is a Gammabody™ that targets CD1d-expressing tumors,uniquely activates both Vγ9Vδ2 T cells as well as invariant natural killer T cells, which represent another conserved immune effector cell population, in a target-dependent manner.

                            Brand Name : LAVA-051

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            October 07, 2022

                            Lead Product(s) : LAVA-051

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Lava Therapeutics

                            Netherlands arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Lava Therapeutics

                            Netherlands arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : LAVA-1223

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Recipient : Seagen

                            Deal Size : $700.0 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Seagen and LAVA Therapeutics Announce Exclusive Worldwide License Agreement to Advance LAVA-1223, a Preclinica...

                            Details : Under the terms of the agreement, Seagen will receive an exclusive global license for LAVA-1223 development, regulatory and commercial milestones; and royalties ranging from the single digits to the mid-teens on future sales.

                            Brand Name : LAVA-1223

                            Molecule Type : Large molecule

                            Upfront Cash : $50.0 million

                            September 26, 2022

                            Lead Product(s) : LAVA-1223

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Recipient : Seagen

                            Deal Size : $700.0 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Lava Therapeutics

                            Netherlands arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Lava Therapeutics

                            Netherlands arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : LAVA-051

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            LAVA Therapeutics Highlights Encouraging Clinical Updates on Lead Program, LAVA-051, in Chronic Lymphocytic Le...

                            Details : LAVA-051 is a humanized Gammabody™ designed to activate both Vγ9Vδ2 (Vgamma9 Vdelta2) T cells and type 1 NKT cells to kill CD1d-expressing tumor cells.

                            Brand Name : LAVA-051

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            June 16, 2022

                            Lead Product(s) : LAVA-051

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Lava Therapeutics

                            Netherlands arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Lava Therapeutics

                            Netherlands arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : LAVA-051

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            LAVA Therapeutics to Present Initial Phase 1/2a Clinical Trial Dose Escalation Data of LAVA-051 in Chronic Lym...

                            Details : The dose-escalation data demonstrated a favorable safety profile to date and early encouraging signs of potential anti-tumor activity of LAVA-051, as well as a desirable PK-PD profile, in patients with chronic lymphocytic leukemia and multiple myeloma.

                            Brand Name : LAVA-051

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            June 01, 2022

                            Lead Product(s) : LAVA-051

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Lava Therapeutics

                            Netherlands arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Lava Therapeutics

                            Netherlands arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : LAVA-051

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            LAVA Therapeutics to Present Updated LAVA-051 Clinical Data at the 2022 American Society of Clinical Oncology ...

                            Details : LAVA-051, is a Gammabody that targets CD1d-expressing tumors, demonstrated efficacy and safety in a variety of preclinical models,it uniquely activates both Vγ9Vδ2 T cells as well as iNKT cells, which represent another conserved immune effector cell po...

                            Brand Name : LAVA-051

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            April 27, 2022

                            Lead Product(s) : LAVA-051

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Lava Therapeutics

                            Netherlands arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Lava Therapeutics

                            Netherlands arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : LAVA-051

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            LAVA Therapeutics Presents Initial LAVA-051 Clinical Data at the ESMO Targeted Anticancer Therapies Congress 2...

                            Details : LAVA-051, a Gammabody designed to activate both Vgamma9 Vdelta2 T cells and type 1 NKT cells to kill CD1d-expressing tumor cells, preliminary data shows encouraging initial clinical safety; no dose-limiting toxicity or cytokine release syndrome.

                            Brand Name : LAVA-051

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            March 07, 2022

                            Lead Product(s) : LAVA-051

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth